Navigation Links
Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
Date:3/21/2011

SAN DIEGO, March 21, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer. The publication is now available on the International Journal of Gynecological Cancer website and scheduled to print in the May issue of the journal.

The study, conducted at Yale-New Haven Hospital, showed that the combination of intravenous Phenoxodiol, a novel NADH oxidase inhibitor, with cisplatin, a platinum-based chemotherapy, was well tolerated and resulted in an overall response rate of 19% (3 out of 16) among ovarian cancer patients previously resistant to platinum. Response rate in this study was defined as the percentage of patients whose tumor demonstrated a radiologically confirmed reduction or disappearance after treatment. An abstract can be found at www.marshalledwardsinc.com/our-programs/scientific-publications that describes more information on the trial results.

"These results suggest that the combination of intravenous Phenoxodiol with cisplatin has a good safety profile and may be capable of reversing resistance to platinum-based chemotherapy," said lead author Michael G. Kelly, MD, a gynecologic oncologist at Tufts Medical Center and former fellow at Yale University School of Medicine." This study provides early clinical proof-of-concept for the combination of NADH oxidase inhibitors with standard-of-care chemotherapy and lays the groundwork for the development of more potent next-generation compounds."

To date, Phenoxodiol, an investigational drug, has been introduced into more than 400 pat
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Receives Positive Response From NASDAQ
2. Marshall Edwards to Host Annual Meeting of Stockholders
3. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
4. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
7. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
8. CCS Medical Announces New President and Chief Executive Officer
9. Echo Therapeutics Announces 2010 Financial Results
10. NeuroFocus Announces Worlds First Wireless Full-Brain EEG Measurement Headset: Mynd™
11. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
(Date:10/22/2014)... 2014   Reproductive Medicine Associates of New ... field of infertility, presents new clinical research examining ... research abstract, released during the 70 th ... in Honolulu, Hawaii , combines ... (SGD) pre-implantation genetic diagnosis (PGD). Results ...
(Date:10/22/2014)... Inc. (NYSE: CRY ), a leading medical ... vascular surgery, announced today that James Patrick (Pat) ... elected to the Company,s Board of Directors, effective October ... Executive Chairman of CryoLife, stated, "Since joining the Company in ... who is well positioned to maximize CryoLife,s potential.  His ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts to ... figures and forecasts on the global medical markets. , ... the Worldwide Medical Market Forecasts to 2019 ... the worldwide medical market to reveal key insights into ... for 2010-2019, covering each country market individually, allowing you ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Women’s health ... in Obstetrics & Gynecology of Columbus, Inc., A Division ... healthcare services to more than 100,000 patients annually. Dr. ... all ages and stages of a women’s life. She ... locations in Westerville and Dublin. , Dr. Murphy ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... research suggests that testosterone replacement therapy for men with ... the prostate gland, contrary to some reports that this ... the November 15 issue of JAMA, a theme issue ... of the Urological Sciences Research Foundation and University of ...
... completely prevented the development of bone tumors in 50 ... providing early evidence that it could treat, or thwart, ... a number of cancers when they start to spread. ... D. Anderson Cancer Center reported in the journal Cancer ...
... symptoms who received a combination therapy were more likely to ... medication, according to a study in the November 15 issue ... ,Steven A. Kaplan, M.D., of Weill Cornell Medical College, ... a JAMA media briefing on men's health in New York. ...
... Family Welfare Minister has said that to shut out ... name of safety would be// against the interest of ... two day International Conclave on Traditional Medicine, which he ... society we live in today, a significant segment of ...
... been sequencing the genome of an organism called Mycobacterium-w ... complete// genome that holds promise in the treatment of ... evidence that a vaccine made from killed Mw drastically ... resistant (MDR) variety is driving this project more than ...
... medical research team looking for a cure for Duchenne Muscular ... submitted their findings// recently. ,The Stem cell Studies ... hope for those who suffer from the disease. ... genetic origin that results in muscle wasting which usually ...
Cached Medicine News:Health News:Testosterone Replacement Therapy Appears Safe for Prostate 2Health News:"Trojan Horse" Agent Halts Bone Metastasis in Mice 2Health News:"Trojan Horse" Agent Halts Bone Metastasis in Mice 3Health News:Combination Therapy More Effective for Treating Lower Urinary Tract Symptoms 2Health News:Two Day International Conclave on Traditional Medicine Inaugurated 2Health News:Two Day International Conclave on Traditional Medicine Inaugurated 3Health News:India Finds New Use for an Old Bug 2Health News:India Finds New Use for an Old Bug 3
... drainage from the ureteropelvic junction to the ... ease of placement and patient compliance. The ... repositioning and ease of removal. AQ® is ... when activated, attracts and holds water and ...
The ARC Laser MISC combines a pharo unit + Lyla laser module = Photolysis....
... IgM Capture ELISA is for the qualitative ... recombinant antigens (WNRA) in serum as an ... West Nile virus infection in patients with ... must be confirmed by Plaque Reduction Neutralization ...
Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
Medicine Products: